Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05479812). This is a study registration, not published results. Lead sponsor: Werewolf Therapeutics, Inc.. Recruitment status: COMPLETED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 156 participants (ACTUAL). Conditions: Metastatic Solid Tumor, Advanced Solid Tumor. Interventions: DRUG: WTX-124; DRUG: pembrolizumab. Primary outcome measures: Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapy , 4 weeks; Incidence of treatment emergent adverse events in monotherapy and combination therapy , 24 months; Incidence of changes in clinical laboratory abnormalities in monotherapy and combination therapy , 24 months; Dose Expansion - Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapy , 4 weeks; Dose Expansion - Incidence of treatment emergent adverse events in monotherapy and combination therapy , 24 months; Dose Expansion - Incidence of changes in clinical laboratory abnormalities in monotherapy and combination therapy , 24 months; Dose Expansion - Investigator-assessed objective response rate (ORR) per RECIST 1.1 and iORR by iRECIST in monotherapy and combination therapy , 24 months. Brief summary: A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.